E-LIB Suche - Ergebnisse für: Roschewski, M.

1

MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYS..:

Roschewski, M. ; Kurtz, D. M. ; Westin, J....
Hematological Oncology. 41 (2023) S2 - p. 177-179 , 2023

Link: https://doi.org/10.1002/..

2

PHASE 2 STUDY OF IBRUTINIB WITH TEMOZOLOMIDE, ETOPOSIDE, LI..:

Roschewski, M. ; Simard, J. ; Melani, C....
Hematological Oncology. 41 (2023) S2 - p. 44-46 , 2023

Link: https://doi.org/10.1002/..

3

Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenali..:

Melani, C. J. ; Lakhotia, R. ; Pittaluga, S....
Hematological Oncology. 41 (2023) S2 - p. 582-584 , 2023

Link: https://doi.org/10.1002/..

4

PHASED VARIANTS IMPROVE DLBCL MINIMAL RESIDUAL DISEASE DETE..:

Kurtz, D. M ; Chabon, J. J ; Soo, J...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

5

THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB ..:

Advani, R. ; Bartlett, N.L. ; Smith, S.M....
Hematological Oncology. 37 (2019) S2 - p. 89-90 , 2019

Link: https://doi.org/10.1002/..

6

PHASE 1B STUDY OF ViPOR (VENETOCLAX, IBRUTINIB, PREDNISONE,..:

Melani, C.J. ; Lakhotia, R. ; Pittaluga, S....
Hematological Oncology. 37 (2019) S2 - p. 332-333 , 2019

Link: https://doi.org/10.1002/..

7

RISK‐ADAPTED THERAPY IN ADULTS WITH BURKITT LYMPHOMA: UPDAT..:

Dunleavy, K. ; Roschewski, M. ; Abramson, J.S....
Hematological Oncology. 35 (2017) S2 - p. 133-134 , 2017

Link: https://doi.org/10.1002/..

8

PHASED VARIANTS IMPROVE DLBCL MINIMAL RESIDUAL DISEASE DETE..:

Kurtz, D. M ; Chabon, J. J ; Soo, J...
url:https://www.openaccessrepository.it/communities/itmirror. , 2021

Link: https://www.openaccessre..

9

BTK drives neutrophil activation for sterilizing antifungal..:

Desai, Jigar V. ; Zarakas, Marissa A. ; Wishart, Andrew L....
Journal of Clinical Investigation. 134 (2024) 12 - p. , 2024

Link: https://doi.org/10.1172/..

10

Specificity of immunoglobulin high-throughput sequencing mi..:

Shukla, Navika D. ; Schroers-Martin, Joseph G. ; Sworder, Brian J....
Blood Advances. 8 (2024) 3 - p. 780-784 , 2024

Link: https://doi.org/10.1182/..

11

ABCL-187 Phase 2 Response-Adapted Study of Ibrutinib With T..:

Simard, Jillian ; Phelan, James D ; Melani, Christopher...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S424-S425 , 2023

Link: https://doi.org/10.1016/..

12

Doxorubicin pharmacokinetics and toxicity in patients with ..:

Lai, Catherine ; Cole, Diane E. ; Steinberg, Seth M....
Blood Advances. 7 (2023) 4 - p. 529-532 , 2023

Link: https://doi.org/10.1182/..

13

Role of Artificial Intelligence in PET/CT Imaging for Manag..:

Veziroglu, Eren M. ; Farhadi, Faraz ; Hasani, Navid...
Seminars in Nuclear Medicine. 53 (2023) 3 - p. 426-448 , 2023

Link: https://doi.org/10.1053/..

14

Prognostic factors for adult patients with Burkitt lymphoma..:

Lakhotia, Rahul ; Dunleavy, Kieron ; Abramson, Jeremy S....
Blood Advances. 7 (2023) 18 - p. 5320-5324 , 2023

Link: https://doi.org/10.1182/..

15

Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) i..:

Roschewski, Mark ; Patel, Manish R. ; Reagan, Patrick M....
Clinical Cancer Research. 29 (2023) 17 - p. 3301-3312 , 2023

Link: https://doi.org/10.1158/..